跳至主要内容
临床试验/ISRCTN12461724
ISRCTN12461724已完成未知

HbA1c TargeT AcheIvemeNt in diabeteS. Psychometric and biomedical outcomes of HbA1c target-setting in adults with Type 1 and Type 2 diabetes: A mixed-methods parallel-group randomised feasibility study

St Helens and Knowsley Teaching Hospitals NHS Trust0 个研究点目标入组 50 人开始时间: 2021年6月11日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
50

研究概览

简要总结

2022 Protocol article in https://pubmed.ncbi.nlm.nih.gov/36302049/ (added 28/10/2022) 2023 Abstract results in https://doi.org/10.1111/dme.15048 Abstracts P300, P302 and P303. Presented at the Diabetes UK Professional Conference 2023. (added 04/08/2023) 2023 Abstract results in https://doi.org/10.2337/db23-1056-P Presented at the American Diabetes Association (ADA) conference (added 04/08/2023)

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • Sub-study A:
  • 1. Aged 18 and over.
  • 2. Has Type 1 or Type 2 Diabetes.
  • 3. HbA1c >/=64;
  • Sub-study B:
  • 1. Enrolled in study A.
  • Sub-study C:
  • 1. Healthcare professional directly involved in the care of people with diabetes.
  • Sub-study D:
  • 1. Eligible patients declining entry into sub-study A will be approached for inclusion in study D.

排除标准

  • Sub-study A:
  • 1. Patients at risk of CVD events.
  • 2. Patients with an episode of severe hypoglycaemia with the past 12 months.
  • 3. Patients with hypoglycaemia unawareness (defined as a GOLD score =4).
  • 4. Patients unwilling to self-monitor blood glucose at home (if clinical management requires).
  • 5. Patients unwilling to inject insulin (if clinical management requires).
  • 6. BMI =45 kg/m².
  • 7. Patients who have opted-out from being contacted by researchers under the NHS national data opt-out service.
  • 8. Patients with other serious illnesses which may limit survival or factors which may limit adherence to study interventions.
  • 9. Patients currently participating in another clinical trial.
  • 10. Patients with a transplanted organ.
  • 11. Pregnancy.
  • 12. Patients with requirements for regular blood transfusion or venesection.
  • 13. Ongoing medical therapy known to cause difficulties with glycaemic control (e.g. corticosteroid therapy).

研究者

发起方
St Helens and Knowsley Teaching Hospitals NHS Trust

相似试验